TY - JOUR
T1 - Immunologic Effects of Sirolimus in Patients with Vascular Anomalies
AU - Nozawa, Akifumi
AU - Ozeki, Michio
AU - Yasue, Shiho
AU - Endo, Saori
AU - Kawamoto, Norio
AU - Ohnishi, Hidenori
AU - Fumino, Shigehisa
AU - Furukawa, Taizo
AU - Tajiri, Tatsuro
AU - Maekawa, Takanobu
AU - Fujino, Akihiro
AU - Sozaki, Ryota
AU - Fukao, Toshiyuki
N1 - Funding Information:
Supported in part by the Clinical Research-Clinical Trial Promotion Research Project (18lk0201055h0003) and the Practical Research Project for Rare/Intractable Diseases (18ek0109277h0002) from the Japan Agency for Medical Research and Development (AMED).
Publisher Copyright:
© 2019 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2020/7/1
Y1 - 2020/7/1
N2 - Emerging data have suggested that sirolimus may be a treatment option for complicated vascular anomalies (VAs). The present study aimed to investigate the immunologic effects of sirolimus treatment for 6 months in patients with VAs. Blood samples obtained from the patients enrolled in 2 multicenter studies to investigate the efficacy of sirolimus for VAs before and after sirolimus treatment for 6 months were used. Data for total white blood cell count, absolute lymphocyte count, serum immunoglobulins (Igs) levels (IgG, IgA, IgM), lymphocyte proliferation assays with mitogens including phytohemagglutinin and concanavalin A, and flow cytometric analysis of lymphocyte subsets were evaluated. A total of 18 patients with VAs receiving sirolimus treatment were included in the study. Comparisons of white blood cell, absolute lymphocyte count, IgG, IgA, IgM, and reaction rates of phytohemagglutinin and concanavalin A revealed no significant differences before and after treatment. No significant differences were observed in the absolute counts of lymphocyte subtypes before and after treatment, except for regulatory T-cell counts, which were significantly decreased after treatment. Severe infections were not observed during sirolimus treatment. The immunologic parameters assessed in the present study were hardly affected by sirolimus treatment for 6 months in patients with VAs.
AB - Emerging data have suggested that sirolimus may be a treatment option for complicated vascular anomalies (VAs). The present study aimed to investigate the immunologic effects of sirolimus treatment for 6 months in patients with VAs. Blood samples obtained from the patients enrolled in 2 multicenter studies to investigate the efficacy of sirolimus for VAs before and after sirolimus treatment for 6 months were used. Data for total white blood cell count, absolute lymphocyte count, serum immunoglobulins (Igs) levels (IgG, IgA, IgM), lymphocyte proliferation assays with mitogens including phytohemagglutinin and concanavalin A, and flow cytometric analysis of lymphocyte subsets were evaluated. A total of 18 patients with VAs receiving sirolimus treatment were included in the study. Comparisons of white blood cell, absolute lymphocyte count, IgG, IgA, IgM, and reaction rates of phytohemagglutinin and concanavalin A revealed no significant differences before and after treatment. No significant differences were observed in the absolute counts of lymphocyte subtypes before and after treatment, except for regulatory T-cell counts, which were significantly decreased after treatment. Severe infections were not observed during sirolimus treatment. The immunologic parameters assessed in the present study were hardly affected by sirolimus treatment for 6 months in patients with VAs.
UR - http://www.scopus.com/inward/record.url?scp=85075403538&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075403538&partnerID=8YFLogxK
U2 - 10.1097/MPH.0000000000001650
DO - 10.1097/MPH.0000000000001650
M3 - Article
C2 - 31743321
AN - SCOPUS:85075403538
VL - 42
SP - e355-e360
JO - Journal of Pediatric Hematology/Oncology
JF - Journal of Pediatric Hematology/Oncology
SN - 1077-4114
IS - 5
ER -